VALacyclovir for Inflammation AttenuatioN Trial Pilot (VALIANT Pilot).
Phase of Trial: Phase III
Latest Information Update: 20 May 2016
At a glance
- Drugs Valaciclovir (Primary)
- Indications Herpes simplex virus type 2 infections; HIV-1 infections
- Focus Biomarker; Pharmacodynamics
- Acronyms VALIANT-Pilot
- 10 Jun 2017 Biomarkers information updated
- 10 May 2016 Status changed from recruiting to completed.
- 22 Dec 2010 Planned end date changed from 1 Aug 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.